Under the European approval, NSCLC therapy with<unk>  is contraindicated when there is tumour cavitation, or if major vessels are involved.
Ramucirumab
Ustekinumab
Emapalumab
Olaratumab
Evolocumab
Avelumab
Anifrolumab
Burosumab